Company intelligence / Profile preview

Guoyao Group Zhonglian Pharmaceutical

Hubei, China

Ownership: Private
Development stage: Other

Overview

Sinopharm Group Zhonglian Pharmaceutical is a major producer of Traditional Chinese Medicine (TCM) in China. Its flagship products, Biejiajian Pill and Jinye Baidu Granules, are exclusive national essential medicines. Research has demonstrated that Biejiajian Pill effectively inhibits hepatocellular carcinoma progression and metastasis by targeting the Akt/GSK-3beta/Snail pathway and enhancing immune cell infiltration. Jinye Baidu Granules are widely used for the treatment of viral respiratory infections, including influenza and COVID-19.

Therapeutic areas: HematologyWomen's HealthInfectious DiseasesGastroenterologyOncology
Modalities: Traditional Chinese MedicineSmall moleculePeptides
Industry: Pharma

Beyond the preview

Go deeper on Guoyao Group Zhonglian Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guoyao Group Zhonglian Pharmaceutical.

Explore the full profile